ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,629.00
0.55%
S&P ASX All Technology
3,016.30
1.48%
Brent Oil
84.00
0.44%
US Dollar vs AUD
1.52131
-0.04%
Bitcoin
59,397.84
0.47%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Roche Holding Ag (0QQ6)

  7. Roche Holding Ag (0QQ6) News

0QQ6 Roche Holding Ag

229.20
0.00 (0.00%)
Last Updated: 10:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Roche Holding Ag 0QQ6 London Ordinary Share
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.00 0.00% 229.20 10:00:00
Open Price Low Price High Price Close Price Previous Close
229.20
more quote information »

Recent News

Date Time Source Heading
24/4/202415:00UKREG[Ad hoc announcement pursuant to Art. 53 LR] Roche sales..
24/4/202415:00UKREG[Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der..
19/4/202415:00UKREGFDA approves Roche’s Alecensa as the first adjuvant..
17/4/202416:00UKREGRoche’s subcutaneous OCREVUS one-year data demonstrates..
15/4/202415:00UKREG[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi..
11/4/202415:00UKREGRoche granted FDA Breakthrough Device Designation for blood..
27/3/202403:45UKREGRoche receives FDA approval for the first molecular test to..
12/3/202423:30UKREGRoche Annual General Meeting 2024
12/3/202423:30UKREGAssemblée générale 2024 de Roche
12/3/202423:30UKREGRoche Generalversammlung 2024
05/3/202423:30UKREGRoche and Alnylam report positive topline results from the..
26/2/202406:00UKREGNew England Journal of Medicine publishes Phase III data..
17/2/202403:24UKREGFDA approves Xolair as first and only medicine for children..
01/2/202417:03UKREGNew long-term data for Roche’s Vabysmo show sustained..
01/2/202417:00UKREG[Annonce événementielle au sens de l’art. 53 RC] Roche..
01/2/202417:00UKREG[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds..
01/2/202417:00UKREG[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche übertrifft..
16/1/202417:00GLOBEEuropean Commission approves Roche’s Tecentriq SC, the EU's..
30/12/202308:30GLOBERoche enters into a definitive agreement to acquire..
20/12/202301:40GLOBEFDA grants priority review to Xolair (omalizumab) for..
15/12/202317:15GLOBERoche named among top three most sustainable healthcare..
11/12/202317:00GLOBENew data for Roche’s Columvi and Lunsumio presented at ASH..
10/12/202303:30GLOBENew data reinforce the benefit of early preventative..
09/12/202303:50GLOBERoche's Kadcyla is the first targeted therapy to show..
09/12/202303:45GLOBERoche’s inavolisib combination reduces the risk of disease..
05/12/202317:00GLOBERoche announces positive Phase III results for inavolisib..
04/12/202317:00GLOBERoche enters into a definitive merger agreement to acquire..
27/11/202317:00GLOBERoche expands hepatitis diagnostics portfolio to help..
16/11/202317:00GLOBERoche launches automated serology hepatitis E virus tests,..
14/11/202317:00GLOBERoche’s subcutaneous injection of Tecentriq recommended by..
09/11/202317:00GLOBERoche’s Elecsys NfL test, an important aid for those living..
31/10/202307:01GLOBE[Ad hoc announcement pursuant to Art. 53 LR] Roche announces..
27/10/202316:00GLOBE[Ad hoc announcement pursuant to Art. 53 LR] FDA approves..
23/10/202322:18IHMARKETNEWSMonday’s Wall Street Highlights: Philips, Chevron,..
23/10/202316:00GLOBE[Ad hoc announcement pursuant to Art. 53 LR] Roche enters..
19/10/202316:00GLOBE[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit gutem..
18/10/202316:03GLOBERoche IL-6 is the first immunoassay approved to aid sepsis..
18/10/202316:00GLOBERoche’s Alecensa reduces the risk of disease recurrence or..
14/10/202300:30GLOBELate-breaking data for Roche’s BTK inhibitor fenebrutinib..
12/10/202316:00GLOBENew data for Roche’s OCREVUS show that after 10 years of..
11/10/202317:00GLOBERoche’s OCREVUS twice-yearly, 10-minute subcutaneous..
10/10/202316:00GLOBERoche’s Vabysmo maintained vision improvements with extended..
04/10/202316:00GLOBEMajority of newborn babies with spinal muscular atrophy..
02/10/202316:00GLOBERoche to present new key clinical and real-world data at..
07/9/202321:00GLOBERoche and Alnylam report positive topline results from Phase..
01/9/202315:00GLOBERoche’s Alecensa delivers unprecedented Phase III results..
29/8/202319:00GLOBERoche’s Tecentriq becomes the first subcutaneous..
29/8/202315:00GLOBEEuropean Commission approves Roche’s Evrysdi for babies..
23/8/202315:22GLOBE[Ad hoc announcement pursuant to Art. 53 LR] Roche provides..
27/7/202315:00GLOBE[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche verzeichnet..

Your Recent History

LSE
0QQ6
Roche
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved